Focusing empowerment, illuminating the path forward for company development

On the morning of January 14, 2025, Liu Bing, member of the Party Leadership Group and Deputy Director of the Provincial Development and Reform Commission, along with relevant personnel from the Yangtze River Economic Belt Development Division and the High-Tech Division, visited our company for a research trip, accompanied by Chen Kelong, Party Secretary and Director of the Municipal Development and Reform Commission. Yao Xiaodong, General Manager of the company, warmly received them, with Huang Mingchun, Deputy Secretary of the District Party Committee, accompanying throughout.

Liu Bing's group first visited the company's integrated workshop to gain an in-depth understanding of the actual production situation. Afterwards, they visited the company's Jiangxi Provincial Engineering Research Center for Immunobiologic Antibody Drugs, inquiring in detail about its operation model and research progress. During the visit, General Manager Yao Xiaodong gave Liu Bing and his team a comprehensive introduction to the company's industrial development layout, showcasing the company's development in the biopharmaceutical industry chain from product R&D to market expansion, and from technological innovation to talent cultivation.

Liu Bing highly commended the company's achievements in industrial chain development. He pointed out that the company's outstanding performance in the industry has not only made significant contributions to local economic development but also set a benchmark for the development of related industries across the province. In addition, Liu Bing carefully listened to the company's engineering research center's report on leveraging project advantages and attracting talent from both at home and abroad. He engaged in in-depth discussions with the company on how to further leverage its strengths and conduct clinical trials for new products, offering valuable guidance.

This research trip has provided direction for the company's development. The company will take advantage of this momentum, continuously optimize its biopharmaceutical industry layout, increase investment in scientific research and innovation, actively attract and cultivate professional talent, and strive to promote local economic growth and overall industry upgrading. The company will forge ahead in the new journey of the biopharmaceutical industry, continuing to empower regional development.